Soto-Pedre E, Newey PJ, Leese GP (2023) Stable incidence and increasing prevalence of primary hyperparathyroidism in a population-based study in Scotland. J Clin Endocrinol Metab 108(10):e1117–e1124. https://doi.org/10.1210/clinem/dgad201

Article  PubMed  PubMed Central  Google Scholar 

Press DM, Siperstein AE, Berber E, Shin JJ, Metzger R, Monteiro R, Mino J, Swagel W, Mitchell JC (2013) The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery 154(6):1232–7. https://doi.org/10.1016/j.surg.2013.06.051. (discussion 7-8)

Article  PubMed  Google Scholar 

Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML, Endocrine S (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97(9):2990–3011. https://doi.org/10.1210/jc.2012-1230

Article  CAS  PubMed  Google Scholar 

Eastell R, Brandi ML, Costa AG, D’Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3570–3579. https://doi.org/10.1210/jc.2014-1414

Article  CAS  PubMed  Google Scholar 

Bilezikian JP (2018) Primary Hyperparathyroidism. J Clin Endocrinol Metab 103(11):3993–4004. https://doi.org/10.1210/jc.2018-01225

Article  PubMed  PubMed Central  Google Scholar 

Thakker RV (2016) Genetics of parathyroid tumours. J Intern Med 280(6):574–583. https://doi.org/10.1111/joim.12523

Article  CAS  PubMed  Google Scholar 

Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, Melton LJ 3rd (2006) Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Miner Res 21(1):171–177. https://doi.org/10.1359/jbmr.050910

Article  PubMed  Google Scholar 

Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, Haigh PI, Adams AL (2013) Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 98(3):1122–1129. https://doi.org/10.1210/jc.2012-4022

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walker MD, Silverberg SJ (2018) Primary hyperparathyroidism. Nat Rev Endocrinol 14(2):115–125. https://doi.org/10.1038/nrendo.2017.104

Article  CAS  PubMed  Google Scholar 

Lemos MC, Thakker RV (2008) Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29(1):22–32. https://doi.org/10.1002/humu.20605

Article  CAS  PubMed  Google Scholar 

Hannan FM, Nesbit MA, Christie PT, Fratter C, Dudley NE, Sadler GP, Thakker RV (2008) Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab 4(1):53–58. https://doi.org/10.1038/ncpendmet0718

Article  CAS  PubMed  Google Scholar 

Hannan FM, Nesbit MA, Christie PT, Lissens W, Van der Schueren B, Bex M, Bouillon R, Thakker RV (2010) A homozygous inactivating calcium-sensing receptor mutation, Pro339Thr, is associated with isolated primary hyperparathyroidism: correlation between location of mutations and severity of hypercalcaemia. Clin Endocrinol (Oxf) 73(6):715–722. https://doi.org/10.1111/j.1365-2265.2010.03870.x

Article  CAS  PubMed  Google Scholar 

Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A, Friedman E, Bernstein-Molho R, Tirosh A (2023) Germline CDKN1B variant type and site are associated with phenotype in MEN4. Endocr Relat Cancer 30(1):e220174. https://doi.org/10.1530/erc-22-0174

Article  CAS  PubMed  Google Scholar 

Mazarico-Altisent I, Capel I, Baena N, Bella-Cueto MR, Barcons S, Guirao X, Albert L, Cano A, Pareja R, Caixàs A, Rigla M (2023) Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism. J Endocrinol Invest 46(4):829–840. https://doi.org/10.1007/s40618-022-01948-7

Article  CAS  PubMed  Google Scholar 

Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil N et al (2012) MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18(10):2828–2837. https://doi.org/10.1158/1078-0432.CCR-12-0160

Article  CAS  PubMed  Google Scholar 

Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, Dwight T et al (2021) Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab 106(4):1163–1182. https://doi.org/10.1210/clinem/dgaa957

Article  PubMed  Google Scholar 

Roszko KL, Blouch E, Blake M, Powers JF, Tischler AS, Hodin R et al (2017) Case report of a prolactinoma in a patient with a novel MAX mutation and bilateral pheochromocytomas. J Endocr Soc 1(11):1401–1407. https://doi.org/10.1210/js.2017-00135

Article  PubMed  PubMed Central  Google Scholar 

Petignot S, Daly AF, Castermans E, Korpershoek E, Scagnol I, Beckers P et al (2020) Pancreatic neuroendocrine neoplasm associated with a familial MAX deletion. Horm Metab Res 52(11):784–787. https://doi.org/10.1055/a-1186-0790

Article  CAS  PubMed  Google Scholar 

Daly AF, Castermans E, Oudijk L, Guitelman MA, Beckers P, Potorac I et al (2018) Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocr Relat Cancer 25(5):L37-l42. https://doi.org/10.1530/erc-18-0065

Article  CAS  PubMed  Google Scholar 

Charoenngam N, Mannstadt M (2023) Primary hyperparathyroidism in a patient with bilateral pheochromocytoma and a mutation in the tumor suppressor MAX. JCEM Case Rep 1(1). https://doi.org/10.1210/jcemcr/luad006

Kobza AO, Dizon S, Arnaout A (2018) Case report of bilateral pheochromocytomas due to a novel max mutation in a patient known to have a pituitary prolactinoma. AACE Clinical Case Rep 4(6):e453–e456. https://doi.org/10.4158/ACCR-2018-0146

Article  Google Scholar 

Mamedova E, Vasilyev E, Petrov V, Buryakina S, Tiulpakov A, Belaya Z (2021) Familial acromegaly and bilateral asynchronous pheochromocytomas in a female patient with a MAX mutation: a case report. Front Endocrinol (Lausanne) 12:683492. https://doi.org/10.3389/fendo.2021.683492

Article  PubMed  Google Scholar 

Tora R, Welch J, Sun J, Agarwal SK, Bell DA, Merino M, Weinstein LS, Simonds WF, Jha S (2023) Phenotypic profiling and molecular mechanisms in hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab dgad368. https://doi.org/10.1210/clinem/dgad368

van der Tuin K, Tops CMJ, Adank MA, Cobben J-M, Hamdy NAT, Jongmans MC et al (2017) CDC73-related disorders: clinical manifestations and case detection in primary hyperparathyroidism. J Clin Endocrinol Metab 102(12):4534–4540. https://doi.org/10.1210/jc.2017-01249

Article  PubMed  Google Scholar 

Erickson LA, Mete O, Juhlin CC, Perren A, Gill AJ (2022) Overview of the 2022 WHO classification of parathyroid tumors. Endocrine Pathol 33(1):64–89. https://doi.org/10.1007/s12022-022-09709-1

Article  Google Scholar 

Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349(18):1722–1729. https://doi.org/10.1056/NEJMoa031237

Article  CAS  PubMed  Google Scholar 

Hannan FM, Nesbit MA, Zhang C, Cranston T, Curley AJ, Harding B, Fratter C, Rust N, Christie PT, Turner JJ, Lemos MC, Bowl MR, Bouillon R, Brain C, Bridges N, Burren C, Connell JM, Jung H, Marks E, McCredie D, Mughal Z, Rodda C, Tollefsen S, Brown EM, Yang JJ, Thakker RV (2012) Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet 21(12):2768–2778. https://doi.org/10.1093/hmg/dds105

Article  CAS  PubMed  Google Scholar 

Newey PJ, Bowl MR, Cranston T, Thakker RV (2010) Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat 31(3):295–307. https://doi.org/10.1002/humu.21188

Article  CAS  PubMed  Google Scholar 

Bricaire L, Odou MF, Cardot-Bauters C, Delemer B, North MO, Salenave S, Vezzosi D, Kuhn JM, Murat A, Caron P, Sadoul JL, Silve C, Chanson P, Barlier A, Clauser E, Porchet N, Groussin L, GroupGTE (2013) Frequent large germline HRPT2 deletions in a French national cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98(2):E403-8. https://doi.org/10.1210/jc.2012-2789

Article  CAS  PubMed  Google Scholar 

Khosla S, Ebeling PR, Firek AF, Burritt MM, Kao PC, Heath H 3rd (1993) Calcium infusion suggests a “set-point” abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab 76(3):715–720. https://doi.org/10.1210/jcem.76.3.8445032

Article  CAS  PubMed  Google Scholar 

Singh P, Bhadada SK, Dahiya D, Arya AK, Saikia UN, Sachdeva N, Kaur J, Brandi ML, Rao SD (2020) Reduced calcium sensing receptor (CaSR) expression is epigenetically deregulated in parathyroid adenomas. J Clin Endocrinol Metab 105(9):3015–3024. https://doi.org/10.1210/clinem/dgaa419

Article  PubMed  PubMed Central  Google Scholar 

Eldeiry LS, Ruan DT, Brown EM, Gaglia JL, Garber JR (2012) Primary hyperparathyroidism and familial hypocalciuric hypercalcemia: relationships and clinical implications. Endocr Pract 18(3):412–417. https://doi.org/10.4158/EP11272.RA

Article  PubMed  Google Scholar 

Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P (2021) Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol 17(4):207–224. https://doi.org/10.1038/s41574-021-00468-3

Article  PubMed  Google Scholar 

Romanet P, Mohamed A, Giraud S, Odou MF, North MO, Pertuit M, Pasmant E, Coppin L, Guien C, Calender A, Borson-Chazot F, Beroud C, Goudet P, Barlier A (2019) UMD-MEN1 database: an overview of the 370 MEN1 variants present in 1676 patients from the French population. J Clin Endocrinol Metab 104(3):753–764.